High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. (Q43763239)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

title

High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

1 reference

myelodysplastic syndrome

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

author name string

M Beran

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

H Kantarjian

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

S O'Brien

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

C A Koller

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

F J Giles

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

J Cortes

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

D A Thomas

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

S Faderl

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

S Despa

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

E H Estey

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

language of work or name

English

0 references

publication date

1 October 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

1999-2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

Proposals for the classification of the myelodysplastic syndromes

12 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011015%2992%3A8%3C1999%3A%3AAID-CNCR1538%3E3.0.CO%3B2-B

Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011015%2992%3A8%3C1999%3A%3AAID-CNCR1538%3E3.0.CO%3B2-B

Refractory anemia with excess of blasts in transformation hematologic and clinical study of 52 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011015%2992%3A8%3C1999%3A%3AAID-CNCR1538%3E3.0.CO%3B2-B

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011015%2992%3A8%3C1999%3A%3AAID-CNCR1538%3E3.0.CO%3B2-B

Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011015%2992%3A8%3C1999%3A%3AAID-CNCR1538%3E3.0.CO%3B2-B

Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011015%2992%3A8%3C1999%3A%3AAID-CNCR1538%3E3.0.CO%3B2-B

Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011015%2992%3A8%3C1999%3A%3AAID-CNCR1538%3E3.0.CO%3B2-B

S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011015%2992%3A8%3C1999%3A%3AAID-CNCR1538%3E3.0.CO%3B2-B

Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011015%2992%3A8%3C1999%3A%3AAID-CNCR1538%3E3.0.CO%3B2-B

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011015%2992%3A8%3C1999%3A%3AAID-CNCR1538%3E3.0.CO%3B2-B

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011015%2992%3A8%3C1999%3A%3AAID-CNCR1538%3E3.0.CO%3B2-B

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011015%2992%3A8%3C1999%3A%3AAID-CNCR1538%3E3.0.CO%3B2-B

Analysis of survival by tumor response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011015%2992%3A8%3C1999%3A%3AAID-CNCR1538%3E3.0.CO%3B2-B

Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011015%2992%3A8%3C1999%3A%3AAID-CNCR1538%3E3.0.CO%3B2-B

Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011015%2992%3A8%3C1999%3A%3AAID-CNCR1538%3E3.0.CO%3B2-B

Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011015%2992%3A8%3C1999%3A%3AAID-CNCR1538%3E3.0.CO%3B2-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011015%2992%3A8%3C1999%3A%3AAID-CNCR1538%3E3.0.CO%3B2-B

10.1002/1097-0142(20011015)92:8<1999::AID-CNCR1538>3.0.CO;2-B

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11596013%20AND%20SRC:MED&resulttype=core&format=json

release_henlmewfebccrlb3xs6iao7riy

12 November 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/henlmewfebccrlb3xs6iao7riy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference